Campbell N R, Hasinoff B B
Faculty of Medicine, Memorial University of Newfoundland, St John's, Canada.
Br J Clin Pharmacol. 1991 Mar;31(3):251-5. doi: 10.1111/j.1365-2125.1991.tb05525.x.
Iron-drug interactions of clinical significance may occur in many patients and involve a large number of therapies. Concurrent ingestion of iron causes marked decreases in the bioavailability of a number of drugs. The affected drugs, tetracycline, tetracycline derivatives (doxycycline, methacycline and oxytetracycline), penicillamine, methyldopa, levodopa, carbidopa and ciprofloxacin have diverse chemical structures and clinical effects. The major mechanism of these drug interactions is the formation of iron-drug complexes (chelation or binding of iron by the involved drug). A large number of other important and commonly used drugs such as thyroxine, captopril and folic acid have been demonstrated to form stable complexes with iron. There is little known about the effects of concurrent therapy with iron supplements for most of the drugs.
具有临床意义的铁-药物相互作用可能在许多患者中发生，且涉及大量治疗方法。同时摄入铁会导致多种药物的生物利用度显著降低。受影响的药物，如四环素、四环素衍生物（强力霉素、甲烯土霉素和土霉素）、青霉胺、甲基多巴、左旋多巴、卡比多巴和环丙沙星，具有不同的化学结构和临床作用。这些药物相互作用的主要机制是形成铁-药物复合物（相关药物与铁螯合或结合）。大量其他重要且常用的药物，如甲状腺素、卡托普利和叶酸，已被证明能与铁形成稳定的复合物。对于大多数药物，铁补充剂同时治疗的效果鲜为人知。
